Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients

[1]  V. Gebski,et al.  Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Xian-fu Sun,et al.  Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer , 2015, PloS one.

[3]  M. de Boer,et al.  Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? , 2015, British Journal of Cancer.

[4]  J. Neuhaus,et al.  Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease , 2015, Neurology. Clinical practice.

[5]  P. Arveux,et al.  Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status. , 2015, European journal of cancer care.

[6]  S. Correa,et al.  The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. , 2015, Cancer letters.

[7]  W. Zhu,et al.  MMP-9 is increased in the pathogenesis of gastric cancer by the mediation of HER2 , 2015, Cancer Gene Therapy.

[8]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Y. Piao,et al.  Expression and correlation of matrix metalloproteinase-9 and heparanase in patients with breast cancer , 2014, Medical Oncology.

[10]  A. Goldhirsch,et al.  A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. , 2014, European journal of cancer.

[11]  H. Samonigg,et al.  An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Xiaohong Xu,et al.  Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. , 2014, International journal of clinical and experimental pathology.

[13]  A. Kallioniemi,et al.  The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. , 2013, Breast.

[14]  C. Garbe,et al.  Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy , 2013, PloS one.

[15]  M. de Boer,et al.  Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome , 2013, Breast Cancer Research and Treatment.

[16]  Seho Park,et al.  Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers , 2013, Breast Cancer Research and Treatment.

[17]  I. Brandslund,et al.  Predicting brain metastases of breast cancer based on serum S100B and serum HER2 , 2013, Oncology letters.

[18]  R. Donato,et al.  Functions of S100 proteins. , 2012, Current molecular medicine.

[19]  KyungMann Kim,et al.  Contrasting treatment‐specific survival using double‐robust estimators , 2012 .

[20]  Janet E Brown,et al.  Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients , 2012, Clinical Cancer Research.

[21]  P. Lamy,et al.  HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. , 2012, Cancer treatment reviews.

[22]  Thomas Bachelot,et al.  Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study , 2012, Breast Cancer Research.

[23]  D. Noh,et al.  The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer , 2012, BMC Cancer.

[24]  J. Wardlaw,et al.  Correlation of Levels of Neuronal and Glial Markers with Radiological Measures of Infarct Volume in Ischaemic Stroke: A Systematic Review , 2011, Cerebrovascular Diseases.

[25]  F. Bibeau,et al.  Variation d’expression des récepteurs hormonaux et d’HER-2 dans l’évolution du cancer du sein : quelles implications en pratique clinique ? , 2011 .

[26]  G. Romieu,et al.  [Hormone receptors and HER-2 changes during breast cancer progression: clinical implications]. , 2011, Bulletin du Cancer.

[27]  R. Balleine,et al.  HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis , 2011, Breast Cancer Research and Treatment.

[28]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Arnold D K Hill,et al.  Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected]. , 2010, Cancer research.

[30]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Young,et al.  Interaction of Developmental Transcription Factor HOX11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast Cancer , 2010 .

[32]  I. Papassotiriou,et al.  Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease , 2009, BMC Cancer.

[33]  M. Stockler,et al.  Third consensus on medical treatment of metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Namer,et al.  Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Gennari.  The Impact of New Chemotherapeutic and Hormone Agents on Survival in a Population-based Cohort of Women with Metastatic Breast Cancer , 2008 .

[37]  Xìao-chun Xu,et al.  Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer , 2008, International journal of cancer.

[38]  K. Gelmon,et al.  The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.

[39]  S. Nofech-Mozes,et al.  Intratumoral Heterogeneity of HER2/neu in Breast Cancer—A Rare Event , 2007, The breast journal.

[40]  G. Bastert,et al.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.

[41]  S. Pinder,et al.  Prognostic factors for patients with hepatic metastases from breast cancer , 2003, British Journal of Cancer.

[42]  R. Timmerman,et al.  Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J L Pujol,et al.  Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. , 2001, Lung cancer.

[44]  M. Maltoni,et al.  Survival, quality of life and breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  I. Stamenkovic.  Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[46]  P. Lamy,et al.  Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. , 2000, Lung cancer.

[47]  B. Romner,et al.  Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. , 2000, Journal of neurotrauma.

[48]  M. Narabayashi,et al.  Construction and validation of a practical prognostic index for patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .